EUS-GE vs ES for Palliation of Gastric Outlet Obstruction
| 対象疾患 | Gastric Outlet Obstruction |
|---|---|
| 相 | 該当なし |
| スポンサー | Johns Hopkins University |
| ステータス | 完了 |
| 参加者数 | 112 名 |
| 介入（薬剤） | Lumen-apposing metal stent, Self-expandable metal stent |
| 開始日 | 2020年10月26日 |
| 完了日 | 2025年6月14日 |
| 結果公開日 | 2026年7月6日 |
概要
Gastric outlet obstruction (GOO) is a common complication of luminal malignancies which is associated with substantial morbidity. Palliation of GOO has traditionally been through the surgical bypass of the obstructed lumen by creating an opening between the stomach and small intestine. However, In recent years, a less invasive approach, i.e. endoscopic stenting, has gained wide acceptance to treat unresectable malignant gastric outlet obstruction. In this study, the investigators are going to compare the safety and efficacy of the two different endoscopic techniques including Endoscopic ultrasonography-guided gastroenterostomy (EUS-GE) and enteral stenting (ES).
Percentage of Participants With Gastric Outlet Obstruction Recurrence
| EUS-guided Gastroenterostomy (EUS-GE) | 0 Percentage of Participants |
|---|---|
| Enteral Stenting (ES) | 15.4 Percentage of Participants |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Ad — Hoffmann-La Roche
- Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patient — National Cancer Institute (NCI)
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 — National Cancer Institute (NCI)
- Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Un — University of Southern California
- Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresecta — National Cancer Institute (NCI)
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients — National Cancer Institute (NCI)